- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Positron and GE extend buyout deadline
Positron and GE Medical Systems have extended the deadline forPositron to complete its acquisition of GE's PET assets (SCAN7/31/96). The deadline, originally set for the end of last year,has been extended until March 31. Positron, of Houston, TX, saidthe
Positron and GE Medical Systems have extended the deadline forPositron to complete its acquisition of GE's PET assets (SCAN7/31/96). The deadline, originally set for the end of last year,has been extended until March 31. Positron, of Houston, TX, saidthe extension enables it to complete regulatory requirements andto finalize its financing package.
In other Positron news, the company last month announced two PETsystem orders: one to a mobile imaging company that will set upa mobile PET route in the Cleveland area, and another to a customerin the New York City area. Positron now has four PET scanner ordersin its backlog.
Also last month, Positron entered a sales and marketing agreementwith Beijing Aerospace Chang Feng Medical Devices, which willsell Positron PET systems in China. Chang Feng is the largestsupplier of CT and MRI scanners in China, according to Positron.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
